Evoq Therapeutics develops disease-specific immune modulators for cancer immunotherapy, targeting the immune system to enhance its response against tumors. Their approach aims to improve patient outcomes by tailoring treatments to individual cancer profiles, addressing the limitations of conventional therapies.
Funding
$2.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
NIFounders
Product
Problem
Current cancer immunotherapies often have limited efficacy and can cause significant side effects due to their broad impact on the immune system. Traditional approaches may not be tailored to the specific characteristics of individual tumors or the unique immune profiles of patients, leading to suboptimal outcomes.
Solution
Evoq Therapeutics is developing disease-specific immune modulators designed to enhance the immune system's response against tumors while minimizing off-target effects. Their approach focuses on tailoring immunotherapies to individual cancer profiles, aiming to improve patient outcomes by selectively targeting and modulating the immune response. By creating personalized treatments, Evoq seeks to overcome the limitations of conventional therapies and maximize the therapeutic benefit for each patient. This precision approach aims to stimulate the immune system to effectively recognize and eliminate cancer cells, leading to more durable responses and reduced toxicity.
Target Audience
The primary target audience includes individuals fighting autoimmune diseases.
Features
- Development of disease-specific immune modulators for targeted cancer immunotherapy.
- Personalized treatment approach based on individual cancer profiles.
- Modulation of the immune system to enhance its response against tumors.